Lufotrelvir

Source: Wikipedia, the free encyclopedia.
Lufotrelvir
Legal status
Legal status
  • US: Investigational drug
Identifiers
  • [(3S)-3-[(2S)-2-[(4-methoxy-1H-indol-2-yl)formamido]-4-methylpentanamido]-2-oxo-4-[(3S)-2-oxopyrrolidin-3-yl]butoxy]phosphonic acid
JSmol)
  • CC(C)C[C@@H](C(=O)N[C@@H](C[C@@H]1CCNC1=O)C(=O)COP(=O)(O)O)NC(=O)C2=CC3=C(N2)C=CC=C3OC
  • InChI=1S/C24H33N4O9P/c1-13(2)9-18(28-24(32)19-11-15-16(26-19)5-4-6-21(15)36-3)23(31)27-17(10-14-7-8-25-22(14)30)20(29)12-37-38(33,34)35/h4-6,11,13-14,17-18,26H,7-10,12H2,1-3H3,(H,25,30)(H,27,31)(H,28,32)(H2,33,34,35)/t14-,17-,18-/m0/s1
  • Key:FQKALOFOWPDTED-WBAXXEDZSA-N

Lufotrelvir (PF-07304814) is an

antiviral drug developed by Pfizer which acts as a 3CL protease inhibitor.[1] It is a prodrug with the phosphate group being cleaved in vivo to yield the active agent PF-00835231.[2] Lufotrelvir is in human clinical trials for the treatment of COVID-19, and shows good activity against COVID-19 including several variant strains, but unlike the related drug nirmatrelvir it is not orally active and must be administered by intravenous infusion, and so has been the less favoured candidate for clinical development overall.[3][4][5]

See also

References

  1. PMID 33054210
    .
  2. PMID 34663813
    .
  3. PMID 33622961
    .
  4. PMID 33802860
    .
  5. PMID 34029993
    .
drug article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Lufotrelvir&oldid=1190949351"